News

Grenova Announces Katherine Marrs as New CEO to Drive Innovation and Growth

Grenova, an industry leader in sustainable laboratory solutions, has appointed Katherine Marrs as its new Chief Executive Officer (CEO). Marrs succeeds Lane Major, who has served as CEO since 2023 and will continue to support Grenova as a member of the Board of Directors.

Marrs has been instrumental in driving Grenova’s growth strategy as the company’s Chief Commercial Officer for the past 16 months. Her leadership has been pivotal in expanding Grenova’s presence in the European market and enhancing its commitment to sustainability within the Life Sciences industry.

“We are at an exciting juncture, and I am honored to lead Grenova as we drive forward,” said Marrs. “I look forward to building on our team’s accomplishments, enhancing our innovative product portfolio, advancing our automation and integration capabilities, and furthering our commitment to helping laboratories reduce their environmental footprint.”

Lane Major expressed his confidence in Marrs’ ability to lead Grenova into its next chapter. “Katherine has demonstrated remarkable vision and leadership during her time as Chief Commercial Officer. Her deep understanding of our business and commitment to innovation make her the perfect choice to lead Grenova.”

Ted Lundberg, Chairman of the Board of Directors for Grenova and Co-Founder of Peloton Equity, Grenova’s majority owner, said, “Katherine has shown remarkable skill in guiding Grenova’s commercial strategy and building a solid foundation for the company’s future. Her dedication, expertise, and strategic focus have proven invaluable, and we look forward to her continued success as CEO.”

As Grenova continues expanding its solutions, Marrs will leverage her expertise to enhance the company’s position in the market, foster partnerships that align with Grenova’s mission, and drive initiatives that further its dedication to environmental and economic responsibility.

 

Read more here.

Recent News

04/08/2026

Likarda and The Tiny Cargo Company Announce Strategic Partnership to Advance Next-Generation Delivery of Biologics, Peptides and Small Molecules

Likarda, Inc., a leader in hydrogel-based drug delivery technologies, today announced a strategic partnership with Tiny Cargo, an innovator in extracellular vesicle (EV) delivery systems. The collaboration will focus on advancing the delivery of biologics and small molecules by integrating Likarda’s Core-Shell Spherification® (CSS®) platform with Tiny Cargo’s vesicle-based technologies. The partnership is designed to

04/08/2026

ReAlta Life Sciences Closes Oversubscribed $40 Million Financing Round to Advance Pegtarazimod Phase 2 Program in Hypoxic Ischemic Encephalopathy (HIE)

ReAlta Life Sciences Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to potentially revolutionize the treatment of inflammatory disorders, today announced the closing of an oversubscribed $40 million financing. This brings the total capital raised to date to more than $150 million.

04/02/2026

ATCC Receives New CDC Award to Help Fast-track Diagnostic Tests for Future Disease Outbreaks

TCC has been selected by the Centers for Disease Control and Prevention (CDC) Office of Readiness and Response (ORR) for a new five-year contract to support rapid test development during public health emergencies. The award, valued at up to $148 million (IDIQ contract 75D301-25-R-73207), will help ensure that diagnostic tools can be quickly created, validated,